加味参苓白术散联合化疗治疗晚期驱动基因阴性肺脾两虚型非小细胞肺癌的临床效果  

Clinical effect of modified Shenling Baizhu powder combined with chemotherapy in the treatment of advanced driver gene negative non-small cell lung cancer of lung and spleen deficiency type

作　　者：潘旭 唐杰 王坚 PAN Xu;TANG Jie;WANG Jian(Oncology Department,Yixing Traditional Chinese Medicine Hospital,Yixing 214200;Oncology Department,Jiangsu Second Hospital of Traditional Chinese Medicine/the Second Affiliated Hospital of NanjingUniversity of Chinese Medicine,Nanjing 210017,China)

机构地区：[1]宜兴市中医医院肿瘤科,江苏宜兴214200 [2]江苏省第二中医院/南京中医药大学第二附属医院肿瘤科,江苏南京210017

出　　处：《临床医学研究与实践》2025年第7期118-122,共5页Clinical Research and Practice

基　　金：江苏省中医药管理局2020年度省中医药科技发展计划项目(No.YB2020023)。

摘　　要：目的探讨加味参苓白术散联合化疗治疗晚期驱动基因阴性肺脾两虚型非小细胞肺癌(NSCLC)的临床效果。方法选择2022年6月至2023年12月宜兴市中医医院肿瘤科收治的90例晚期驱动基因阴性肺脾两虚型NSCLC患者,按照随机数字表法将其分为西医组和中西医组,各45例。西医组给予西医一线治疗,中西医组在西医组基础上联合加味参苓白术散治疗。比较两组的治疗效果。结果中西医组的症状改善总有效率高于西医组(P<0.05)。中西医组的疾病控制率高于西医组(P<0.05)。治疗后,两组的癌胚抗原(CEA)、神经元特异性烯醇化酶(NSE)、细胞角蛋19片段(CYFRA21-1)、鳞状上皮细胞癌抗原(SCC-Ag)水平低于治疗前,且中西医组低于西医组(P<0.05)。治疗后,两组的Piper疲乏量表(PFS)评分均降低,肿瘤病人生活质量评分表(QOL)评分均升高,且中西医组优于西医组(P<0.05)。中西医组的不良反应总发生率低于西医组(P<0.05)。结论加味参苓白术散联合化疗可提高晚期驱动基因阴性肺脾两虚型NSCLC患者的临床效果,降低CEA、NSE、CYFRA21-1、SCC-Ag等肿瘤标志物表达水平,改善癌性疲乏和生活质量,降低不良反应发生率。Objective To explore the clinical effect of modified Shenling Baizhu powder combined with chemotherapy in the treatment of advanced driver gene negative non-small cell lung cancer(NSCLC)of lung and spleen deficiency type.Methods From June 2022 to December 2023,90 patients with advanced driver gene negative NSCLC of lung and spleen deficiency type admitted in the oncology department of Yixing Traditional Chinese Medicine Hospital were selected.According to the random number table method,the patients were divided into western medicine group and Chinese and western medicine group,with 45 cases in each group.The western medicine group was given first-line treatment of western medicine,and the Chinese and western medicine group was treated with modified Shenling Baizhu powder on the basis of the western medicine group.The therapeutic effects of the two groups were compared.Results The total effective rate of syndrome improvement in the Chinese and western medicine group was higher than that in the western medicine group(P<0.05).The disease control rate of the Chinese and western medicine group was higher than that of the western medicine group(P<0.05).After treatment,the levels of carcinoembryonic antigen(CEA),neuron-specific enolase(NSE),cytokeratin 19 fragment(CYFRA21-1)and squamous cell carcinoma antigen(SCC-Ag)in the two groups were lower than those before treatment,and those in the Chinese and western medicine group were lower than the western medicine group(P<0.05).After treatment,the Piper Fatigue Scale(PFS)score of the two groups decreased,and the Quality of Life Scale for Cancer Patients(QOL)score increased,and those in the Chinese and western medicine group were better than the western medicine group(P<0.05).The total incidence of adverse reactions in the Chinese and western medicine group was lower than that in the western medicine group(P<0.05).Conclusion Modified Shenling Baizhu powder combined with chemotherapy can elevate the clinical effect of advanced driver gene negative NSCLC patients with lung and

关 键 词：参苓白术散 化疗 非小细胞肺癌 肺脾两虚型 晚期驱动基因阴性 

分 类 号：R275.9[医药卫生—中西医结合]